Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.04281171002201745 | N/A |
Market Cap | $12.26M | N/A |
Shares Outstanding | 286.46M | 0.91% |
Employees | 0 | N/A |
Shareholder Equity | 8.70M | -4.33% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -15.86 | N/A |
P/S Ratio | 2.14 | N/A |
P/B Ratio | 1.41 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0597 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $5.73M | N/A |
Earnings | -$519.18K | N/A |
EPS | -0.0027 | N/A |
Earnings Yield | -0.0631 | N/A |
Gross Margin | 0.9338 | N/A |
Operating Margin | -0.4022 | N/A |
Net income margin | -0.0906 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $9.03M | N/A |
Total Debt | $1.60M | N/A |
Cash on Hand | $4.23M | N/A |
Debt to Equity | 0.3586 | -7.96% |
Cash to Debt | $2.65 | -5.61% |
Current Ratio | $4.14 | 37.10% |